Oncolytic Virus Rp1

Cutaneous Melanoma

Replimune, Inc.gene_therapyPhase 2Active

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 81/ 100

Competitive context

141 Active assets in the Cutaneous Melanoma cohort.

Asset / Sponsor	Phase	Rating
Alpha-Interferon MIPO Clinic	Phase 3	BBB
Dacarbazine Linnaeus Therapeutics, Inc.	Phase 3	BBB
Cis-Diamminedichloroplatinum Ii MIPO Clinic	Phase 3	BBB
TIL City of Hope Medical Center	Phase 2	BBB
Tyrosinase Peptide University of Southern California	Phase 3	BBB

View all 50 →

Same molecule, other indications

Oncolytic Virus Rp1 is also rated in:

melanomaActive

B

Indicative · Phase 3

58 / 100

skin carcinomaActive

CCC

Indicative · Phase 2

53 / 100

non-small cell lung carcinomaActive

CCC

Indicative · Phase 2

51 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.